Largest BTC Short Squeeze of $10 Million Scale Hits, Liquidation Price at $80,900
BlockBeats News, April 27, according to Hyperinsight monitoring, on the Hyperliquid platform, among the tens of millions of US dollars worth of BTC short positions, the address closest to liquidation is a whale with an address starting with 0xbac, with a liquidation price of $80,929.
At 10 PM last night, the whale opened a 40x leveraged BTC short position, entering just before the start of this round of price increase, going against the trend. The position currently holds 175 BTC, with a position size of approximately $13.8 million, an entry price of $77,915, and is already at a 54% unrealized loss.
In the past half an hour, the whale has placed a market order, planning to liquidate the position with a stop-loss if BTC falls back to $78,129.
Address: 0xbac2d8e1e3ef8cba378564667be59a2e2d8ed897
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
